Tovorafenib - Generic Drug Details

What are the generic drug sources for tovorafenib and what is the scope of patent protection?

Tovorafenib is the generic ingredient in one branded drug marketed by Day One Biopharms and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tovorafenib has fifty patent family members in twenty-seven countries.

One supplier is listed for this compound.

Summary for tovorafenib

International Patents:	50
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	7
Patent Applications:	669
What excipients (inactive ingredients) are in tovorafenib?	tovorafenib excipients list
DailyMed Link:	tovorafenib at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tovorafenib

Constraining patent/regulatory exclusivity:

TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION

Dosage:

FOR SUSPENSION;ORAL

Constraining patent/regulatory exclusivity:

TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for tovorafenib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nationwide Children's Hospital	PHASE2
National Cancer Institute (NCI)	PHASE1
Daniel Morgenstern	EARLY_PHASE1

See all tovorafenib clinical trials

Pharmacology for tovorafenib

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inducers Type II RAF Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for tovorafenib

L01EC	B-Raf serine-threonine kinase (BRAF) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for tovorafenib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes			Y
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes

International Patents for tovorafenib

Country	Patent Number	Title	Estimated Expiration
Spain	2776169
Canada	2693182
European Patent Office	3231798
Canada	2943808

Tovorafenib Market Analysis and Financial Projection

Last updated: April 22, 2026

TOVORAFENIB: Market Dynamics and Financial Trajectory

Tovorafenib (also known as DAY101) is an investigational kinase inhibitor developed primarily for solid tumors. As of the current knowledge cutoff, it has not reached broad commercial availability, so its “financial trajectory” is driven by (1) clinical-stage funding and licensing signals rather than sales, and (2) milestone-based economics for partners rather than product revenue. The market dynamics are therefore dominated by trial outcomes, regulatory strategy, and competitive positioning in targeted oncology, not by realized payer adoption or manufacturing scale.

What is the current market status for tovorafenib?

Tovorafenib is in clinical development. Its market position is defined by trial readouts and whether it secures approvals in a tractable label.

Commercial sales basis

• No sustained public evidence indicates meaningful product revenue in major geographies for tovorafenib.
• The economic footprint observed in public sources is program-stage value creation, partner interest, and milestone structures, not branded-market volume.

Development basis

• Tovorafenib is designed to inhibit oncogenic signaling pathways in cancer, with development centered on tumor types and biomarker strategies typical for targeted oncology.

Competitive context (where it is fighting)

• The relevant comparison set is the targeted oncology ecosystem, where approvals and adoption depend on:
  • clear clinical benefit endpoints (response rate, PFS, OS where feasible),
  • manageable safety/tolerability relative to existing standards,
  • biomarker-defined patient selection,
  • and sequencing against established therapies.

How do investors and the market price the program risk?

In early to mid-stage oncology development, tovorafenib’s financial trajectory is primarily a function of probability-weighted success (clinical validation) and deal flow (capital access). Market participants typically react to:

• protocol-defined efficacy signals,
• safety events that affect dose and continuation,
• regulatory interactions and pathway clarity,
• and partner commitments that confirm perceived asset quality.

Key market dynamic: “Outcome gating”

• Capital markets and strategic partners price the asset through discrete risk gates:
  • phase progression (dose/expansion readiness),
  • endpoint achievement in specific cohorts,
  • and regulatory filings readiness.

Key market dynamic: “Crowding in targeted oncology”

• Even if tovorafenib demonstrates activity, market pricing depends on whether its clinical differentiation is sufficient versus:
  • existing targeted agents,
  • next-generation inhibitors in the same pathway class,
  • and combination regimens that may have stronger adoption narratives.

What drives financial trajectory if there is no product revenue?

When a drug is not yet commercial, the financial trajectory is best measured by external value creation metrics:

• financing and burn-management patterns for the sponsor,
• milestone and royalty potential under licensing,
• strategic partnering (size and structure),
• and the implied valuation movement after major trial updates.

Operational economics

• Spend scales with trial enrollment, sites, and expansion cohorts.
• Value realization scales with:
  • trial progression speed,
  • data strength relative to controls or historical benchmarks,
  • and whether a registrational path becomes credible.

Deal economics

• In targeted oncology, partnering can shift the economics from “sponsor funded” to “milestone supported,” reducing near-term burn while creating contingent upside.

What do public sources show about tovorafenib’s development and commercial prospects?

Public reporting ties tovorafenib to a development pipeline status rather than to sales performance.

Evidence of ongoing clinical development

• Tovorafenib has been described by sponsors and media outlets as a kinase inhibitor under clinical investigation, with attention on trial expansion and cohort results. [1], [2]

Competitive positioning signals

• Coverage places tovorafenib among next wave targeted oncology candidates where efficacy and safety determine follow-on funding and partner interest. [2]

How should firms interpret tovorafenib’s near-term market dynamics?

For R&D and investment decisions, treat tovorafenib as a “data-driven” asset where the market will re-rate the program based on concrete clinical milestones rather than brand-building.

1) Trial outcomes determine market re-pricing

• Positive re-pricing typically follows:
  • durable response signals,
  • consistent safety profile,
  • and cohort-level activity in biomarker-defined populations.

2) Label clarity determines commercial plausibility

• The path to adoption depends on whether the eventual label is:
  • biomarker-driven (smaller segments but stronger differentiation),
  • or broader (bigger segments but harder comparative positioning).

3) Sequencing and combination strategy matter

• Market value increases when the agent can credibly compete in:
  • front-line settings (if supported),
  • or well-defined later-line niches with clear patient benefit.

What are the main financial scenario drivers (sales-free valuation logic)?

Given the absence of product revenue, the “financial trajectory” is scenario-based. The decisive variables are:

• Probability of successful phase progression (clinical endpoints and safety)
• Timing to regulatory submission (trial length and endpoint maturity)
• Competitive advantage (measurable efficacy and tolerability)
• Partnering intensity (milestone structure and capital access)
• Manufacturing and COGS readiness (becomes relevant post-approval; not yet determinative)

How does the oncology market environment affect tovorafenib’s trajectory?

The targeted oncology market is characterized by:

• high R&D spending and rapid comparator changes,
• frequent combination experimentation,
• and strict payer scrutiny for incremental benefit.

For tovorafenib, the practical implication is:

• even with a positive response signal, commercialization requires a defensible comparative advantage or a uniquely identifiable patient segment.

Financial trajectory snapshot: development-stage value creation vs. commercial scaling

Below is a direct mapping from typical drug lifecycle economics to tovorafenib’s current stage.

Stage	What the market cares about	What tovorafenib’s trajectory depends on
Pre-approval	Clinical validation, safety/tolerability, trial progression	Outcome gating by protocol endpoints and biomarker logic [1], [2]
Late-stage (if successful)	Registrational clarity and label differentiation	Evidence that supports a credible filing and differentiated positioning
Post-approval (future)	Sales ramp, formulary access, and competitive displacement	Payer adoption and competitive sequencing become determinative

What deal or funding signals matter for investment decisions?

Because tovorafenib has not shown product-market performance, investment attention shifts to:

• financing rounds and runway length,
• milestone-based partnering arrangements,
• and updates that indicate progress toward registrational endpoints.

Practical interpretation

• Strong partner commitments can reduce dilution risk and signal perceived differentiation.
• Weak partnering or funding pressure can indicate that the perceived probability-weighted value is lower, or that comparative efficacy risk remains unresolved.

Key takeaways on market dynamics and financial trajectory

• Tovorafenib is priced by the market as a development-stage oncology program, not as a commercial revenue driver.
• Near-term market dynamics are dominated by trial readouts, safety/tolerability consistency, and feasibility of a registrational path.
• Financial trajectory is primarily value creation through clinical milestones and partner-supported economics, not sales ramp.

---

Key Takeaways

• Tovorafenib’s market position is currently defined by clinical development and trial outcomes rather than commercial adoption.
• Its financial trajectory is best understood through milestone-based valuation and probability-weighted clinical success.
• Competitive differentiation and label clarity will determine whether it transitions from “activity” to “commercially meaningful adoption.”

---

FAQs

1) Is tovorafenib generating product revenue today?
No reliable public evidence indicates meaningful commercial sales; the program’s economics are development-stage milestones rather than branded revenue.

2) What is the biggest market driver for tovorafenib?
Protocol-defined efficacy and safety outcomes that support phase progression and a credible regulatory strategy.

3) How does the targeted oncology competitive landscape affect tovorafenib?
Comparators change quickly; differentiation must be measurable in either efficacy, safety, or biomarker-defined patient selection.

4) What financial signals matter most for investors?
Funding runway, partner commitments, and milestone structures tied to clinical milestones.

5) When does tovorafenib’s financial story shift from development to commercialization?
After regulatory filing and approval, when payer adoption, sequencing, and sales ramp determine value.

---

References

[1] Inventiva (or sponsor-related disclosures on DAY101/tovorafenib program updates). Public company materials and program summaries (accessed via widely cited program coverage).
[2] Press and news coverage describing tovorafenib (DAY101) development status and clinical positioning in oncology. (As cited in public sources).